| Description |
Miroestrol is a highly active phytoestrogen. Miroestrol can produce mammogenic effect. Miroestrol exhibits bone loss prevention and neuroprotective in ovariectomized mice. Miroestrol also can reduce cancer risk[1][2][3][4].
|
| Related Catalog |
|
| In Vivo |
Miroestrol (0.1-1 mg/kg; s.c. once daily for 60 days) exhibits bone loss prevention via increase of the ratio of osteoprotegerin to receptor activator of nuclear factor kappa B ligand (osteoformation/osteoresorption) in ovariectomized mouse liver[2]. Miroestrol (0.1-1 mg/kg; i.p. once daily for 8 weeks) dose-dependently attenuates ovariectomized-induced cognitive dysfunction in mice[3]. Miroestrol (0.5-5 mg/kg; s.c. once daily for 7 days) suppresses hepatic CYP1A1 activity and CYP1A2 activity, expression of CYP1B1 mRNA and expression of CYP1A1/2 and CYP1B1 protein in β-naphthoflavone-treated mice[4].
|
| References |
[1]. Kitisripanya T, et, al. A pilot pharmacokinetic study of miroestrol and deoxymiroestrol on rabbit sera using polyclonal antibody-based icELISA analysis. Phytother Res. 2018 Feb;32(2):365-369. [2]. Udomsuk L, et, al. Impact of Pueraria candollei var. mirifica and its potent phytoestrogen miroestrol on expression of bone-specific genes in ovariectomized mice. Fitoterapia. 2012 Dec;83(8):1687-92. [3]. Monthakantirat O, et, al. Effect of miroestrol on ovariectomy-induced cognitive impairment and lipid peroxidation in mouse brain. Phytomedicine. 2014 Sep 25;21(11):1249-55. [4]. Chatuphonprasert W, et, al. Regulation of cancer-related genes - Cyp1a1, Cyp1b1, Cyp19, Nqo1 and Comt - expression in β-naphthoflavone-treated mice by miroestrol. J Pharm Pharmacol. 2016 Apr;68(4):475-84.
|
